What is claimed is:

1. An aqueous pharmaceutical formulation comprising:
aflibercept at a concentration of at least 100 mg/ml;
L-arginine;
a sugar;
a histidine-based buffer; and
a non-ionic surfactant;
wherein the formulation has a pH of 5.0 to 6.8.

2. The formulation of claim 1 which is suitable for intravitreal administration.

3. The formulation of any one of claims 1-2 further comprising sodium sulfate, sodium thiocyanate, glycine, NaCl, sodium aspartate, and/or sodium glutamate.

4. The formulation of any one or claims 1-3, comprising:
aflibercept at a concentration of 103-126 mg/ml;
10 mM ± 1 mM histidine-based buffer;
5% ± 0.5% (w/v) sugar;
0.02-0.04% (w/v) non-ionic surfactant; and
50 mM ± 5 mM L-arginine,
with a pH of 5.5-6.1.

5. The formulation of any one or claims 1-4, consisting of:
aflibercept at a concentration of 103-126 mg/ml;
10 mM ± 1 mM histidine-based buffer;
5% ± 0.5% (w/v) sucrose;
0.02-0.04% (w/v) polysorbate 20; and
50 mM ± 5 mM L-arginine,
with a pH of 5.5-6.1.

6. The formulation of any one of claims 1-5, comprising:
aflibercept at a concentration of 103-126 mg/ml;
10 mM ± 1 mM histidine-based buffer;
5% ± 0.5% (w/v) sucrose;

0.02-0.04% (w/v) polysorbate 20; and
50 mM ± 5 mM L-arginine,
with a pH of 5.5-6.1.

7. The formulation of any one of claims 1-6, wherein the aflibercept is at a concentration of:

- 100 mg/ml;
- 111.5 mg/ml;
- 112.0 mg/ml;
- 113.3 mg/ml;
- 114.3 mg/ml;
- 115.6 mg/ml;
- 116.3 mg/ml;
- 120 mg/ml;
- 133 mg/ml;
- 140 mg/ml;
- 150 mg/ml;
- 200 mg/ml;
- 250 mg/ml; or
- that which contains 8 mg aflibercept in 70 µl.

8. The formulation of any one of claims 1-7 wherein:
(i) the osmolality is 299 to 506 mmol/Kg; and/or
(ii) the viscosity is from 6-15 cP at 20°C.

9. The formulation of any one of claims 1-8 wherein the pH is 5.8 to 6.5.

10. The formulation of claim 9 wherein the pH is 5.8.

11. The formulation of claim 1, comprising:
aflibercept at a concentration of 103-126 mg/ml;
10 mM ± 1 mM histidine-based buffer;
5% ± 0.5% (w/v) sucrose
0.02-0.04% (w/v) polysorbate 20; and
50 mM ± 5 mM L-arginine,

with a pH of 5.5-6.1;

wherein the aflibercept has less than 3.5% high molecular weight species immediately after manufacture and purification and/or less than or equal to 6% high molecular weight species after storage for 24 months at 2-8°C.

12. The formulation of claim 1, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, polyethylene glycol 3350 and mixtures thereof.

13. The formulation of any one of claims 1-12, wherein the histidine-based buffer comprises histidine hydrochloride.

14. The formulation of claim 13 comprising 10 mM to 20 mM histidine-based buffer.

15. The formulation of any one of claims 1-14, wherein the sugar is sucrose.

16. The formulation of any one of claims 1-14, wherein the sugar is mannitol, sorbitol or trehalose.

17. The formulation of any one of claims 15-16 comprising 2.5% (w/v), 5% (w/v), 8% (w/v), 10% (w/v) or 20% (w/v) sugar, which is sucrose, mannitol, sorbitol or trehalose.

18. The formulation of any one of claims 1-17 comprising non-ionic surfactant at a concentration of 0.03% (w/v).

19. The formulation of any one of claims 1-18, wherein the L-arginine is L-arginine monohydrochloride.

20. The formulation of any one of claims 1-19 wherein the aflibercept has less than 3.5% high molecular weight species immediately after manufacture and purification and/or less than or equal to 6% high molecular weight species after storage for 24 months at 2-8°C.

21. A formulation comprising the components in a formulation selected from the group consisting of:
Formulation XX: 140 mg/ml aflibercept, 20 mM histidine-based buffer, 4% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine hydrochloride, with a pH of 5.8;

Formulation ZZ: 140 mg/ml aflibercept, 10 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine hydrochloride, with a pH of 5.8;
Formulation CCC: 80, 100, 120 or 140 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine hydrochloride, with a pH of 5.8;
Formulation OOO: 140 mg/ml aflibercept; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium Citrate; 50 mM L-arginine hydrochloride;
Formulation PPP: 140 mg/ml aflibercept; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50mM glycine; 50 mM L-arginine hydrochloride;
Formulation QQQ: 140 mg/ml aflibercept; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; 50 mM L-arginine hydrochloride;
Formulation RRR: 140 mg/ml aflibercept; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; 50 mM L-arginine hydrochloride;
Formulation SSS: 140 mg/ml aflibercept; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 10 mM L-arginine hydrochloride;
Formulation TTT: 140 mg/ml aflibercept; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 100 mM L-arginine hydrochloride;
Formulation DDDD: 80.0 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation EEEE: 120.0 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation FFFF: 113.3 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation GGGG: 114.3 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation HHHH: 100.0 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation IIII: 133.3 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;
Formulation JJJJ: 150 mg/ml aflibercept, 10 mM sodium phosphate, 8% (w/v) sucrose, 0.03% (w/v) polysorbate 20 and 50 mM L-arginine hydrochloride, pH 6.2; and
Formulation KKKK: 114.3 mg/ml aflibercept, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8.

22. The formulation of claim 21 wherein the aflibercept has less than 3.5% high molecular weight species immediately after manufacture and purification and/or less than or equal to 6% high molecular weight species after storage for 24 months at 2-8°C.

23. A container or injection device comprising the formulation of any one of claims 1-22.

24. The container or injection device of claim 23, which is a vial, syringe, or pre-filled syringe.

25. A method for preparing the formulation of any one of claims 1-22, comprising combining the components of said formulation into a single composition.

26. The method of claim 25, further comprising loading a volume of the formulation into a syringe.

27. A formulation which is the product of the method of any one of claims 25-26.

28. Use of a formulation of any one of claims 1-21 and 26 in the manufacture of a medicament for the treatment of an angiogenic eye disorder in a subject, wherein the medicament is to be administered via intraocular injection into an eye of the subject.

29. Use of aflibercept in a formulation of any one of claims 1-22 or 27 in the manufacture of a medicament for the treatment of an angiogenic eye disorder in a subject, wherein the medicament is to be administered via intraocular injection into an eye of the subject at a dosage of 8 mg or more of the aflibercept.

30. The use of claim 29, wherein the medicament is to be administered into the eye of the subject at a dosage of 8 mg of the aflibercept.

31. The use of any one of claims 29-30, wherein the formulation is to be administered via intravitreal injection.

32. The use of any one of claims 29-31, wherein the angiogenic eye disorder is age-related macular degeneration (wet), macular edema, macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO) branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal

neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy and/or proliferative diabetic retinopathy.

33. The use of any one of claims 31-32 wherein the intravitreal injection of the aflibercept is to be administered at a dosage of 75 microliters or less.

34. The use of any one of claims 29-33, wherein the aflibercept is contained within a formulation comprising: 5% sucrose; a histidine buffer; and 0.03% non-ionic surfactant.

35. The use of any one or claims 31-34 wherein the medicament is to be administered via intravitreal injection of the aflibercept once every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 weeks.

36. The use of any one of claims 31-34, wherein the angiogenic eye disorder is:

age-related macular degeneration (wet);
macular edema following retinal vein occlusion;
diabetic macular edema; or
diabetic retinopathy.